SCHEMBL5405504

SCHEMBL5405504

COc1ccc(-c2cnc(N)nc2-c2c[nH]c(C(=O)N3CCOCC3)c2)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 1/20 0.55
KIT P10721 2/20 0.54
ADORA1 P30542 2/20 0.52
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
MAPK1 P28482 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PIK3CA P42336 1/20 0.44
PKM P14618 2/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
MAP4K1 Q92918 2/20 0.43
IL2 P60568 1/20 0.43
ADORA2A P29274 1/20 0.43
JAK2 O60674 2/20 0.42
JAK1 P23458 2/20 0.42
TYK2 P29597 2/20 0.42
JAK3 P52333 2/20 0.42
LRRK2 Q5S007 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405421 0.90 ADORA1 (0.53) PRKCZKITADORA1KMT2APIK3CA
SCHEMBL5404432 0.90 ADORA1 (0.52) PRKCZKITADORA1MAPTMAPK1
SCHEMBL5400730 0.87 ADORA1 (0.49) PRKCZKITADORA1KMT2APIK3CA
SCHEMBL27582134 0.86 ADORA1 (0.48) PRKCZKITADORA1KMT2APIK3CA
SCHEMBL5407179 0.85 ADORA1 (0.47) PRKCZKITADORA1NPC1PIK3CA
SCHEMBL27582136 0.85 ADORA1 (0.47) PRKCZKITADORA1KMT2APIK3CA
SCHEMBL5401499 0.84 ADORA1 (0.51) ADORA1MEN1KMT2AHPGDCCKAR
SCHEMBL5401255 0.84 MAPK1 (0.51) ADORA1MAPK1KMT2APOLBADORA2A
SCHEMBL5401735 0.84 ADORA1 (0.48) KITADORA1NPC1MEN1KMT2A
SCHEMBL5404667 0.84 ADORA1 (0.52) ADORA1MAPTNPC1MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP claimed
US-6743791-B2 ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS VERTEX PHARMACEUTICALS INCORPORATED 2004-06-01 US claimed
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-15 US claimed
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 US disclosed
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 PRKCZ 859/4885KIT 3117/4885ADORA1 4421/4885
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 PRKCZ 226/4885KIT 3061/4885ADORA1 4106/4885
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 PRKCZ 226/4885KIT 3061/4885ADORA1 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.